Obesity care is no longer about weight alone
Across cardiometabolic sessions, obesity was consistently discussed as a driver of type 2 diabetes, cardiovascular disease, musculoskeletal problems and, increasingly, cancer risk. From a clinical perspective, effective obesity treatment is therefore less about cosmetic weight reduction and more about modifying disease trajectories over time.
It was within this broader, disease-focused context that amylin-based therapies were discussed at ECO—not as standalone “weight-loss drugs,” but as potential future tools in cardiometabolic care.
What GLP-1 therapy has achieved, and where it can fall short
There is no question that GLP-1 receptor agonists have transformed obesity treatment. For many patients, they have delivered levels of weight loss and metabolic improvement that were previously difficult to achieve without surgery.
At the same time, speakers acknowledged a familiar reality in clinic: not every patient responds in the same way, and many experience a plateau after an initial period of success. This was discussed not as failure, but as part of the biological complexity of obesity.
This recognition sets the stage for therapies that work through different biological pathways, rather than simply offering stronger versions of the same mechanism. For context on higher-dose semaglutide alongside other advanced incretin options, see our overview of 7.2 mg Wegovy compared with other high-dose GLP-1s.
Why amylin matters: a different biological lever
Amylin plays a role in appetite regulation and glucose control through pathways that are distinct from GLP-1. Newer amylin analogues are engineered to overcome limitations of the naturally occurring hormone, allowing for sustained clinical effects where the science supports use.
At ECO, this was framed as an opportunity to address unmet needs, particularly in patients whose appetite regulation, glycaemic control or weight trajectory are not fully addressed by incretin-based therapy alone.
Rather than replacing existing treatments, amylin-based approaches were positioned as complementary options within an expanding therapeutic toolkit.
Understanding how amylin-based therapies work
Amylin, also known as islet amyloid polypeptide (IAPP), is a peptide hormone co-secreted with insulin from pancreatic beta cells in response to food intake. While insulin’s role in glucose control is widely recognised, amylin plays a complementary role in regulating satiety, meal termination and post-prandial glucose handling.
Unlike incretin hormones such as GLP-1, which primarily act through hypothalamic appetite pathways, amylin exerts its effects predominantly via the hindbrain, particularly the area postrema and nucleus of the solitary tract—regions involved in detecting circulating metabolic signals and coordinating meal termination rather than general appetite suppression alone.
Key physiological actions of amylin include:
- Promotion of satiety and reduction in meal size.
- Slowing of gastric emptying, reducing rapid post-meal glucose excursions.
- Suppression of glucagon secretion, limiting hepatic glucose output after meals.
Together, these effects help explain why amylin deficiency or dysfunction is associated with both impaired glycaemic control and dysregulated eating behaviour in people living with obesity and type 2 diabetes. Independent reviews discuss amylin physiology and therapeutic development further: PMC open-access article and MDPI review.
CagriSema: clinical evidence for dual amylin–GLP-1 therapy
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. Its development is grounded in peer-reviewed clinical trials exploring whether targeting both satiety and appetite pathways can improve outcomes in obesity and metabolic disease.
In a phase 2, randomised, double-blind trial published in The Lancet, co-administration of cagrilintide and semaglutide resulted in substantially greater weight loss than either agent alone over 32 weeks, alongside meaningful improvements in glycaemic control in people with type 2 diabetes.
More recently, phase 3a data from the REDEFINE programme, reported in The Lancet Diabetes & Endocrinology and The New England Journal of Medicine, have described once-weekly cagrilintide–semaglutide versus semaglutide alone in adults with overweight or obesity, with or without type 2 diabetes, when used alongside lifestyle intervention. As always, headlines from trials need to be interpreted with your own clinician in the context of eligibility, monitoring and NHS availability.
These trials reinforce an important clinical point: enhanced weight loss with CagriSema appears to reflect multi-pathway engagement, rather than dose escalation of a single mechanism alone.
What this signals for the future of obesity treatment
Taken together, mechanistic and clinical evidence supports the idea that obesity is best approached as a biologically heterogeneous disease, where different patients may benefit from different therapeutic pathways—or combinations of pathways—over time.
Peer-reviewed research increasingly suggests amylin-based therapies may play a valuable role:
- in patients with plateaued weight loss on GLP-1 therapy;
- in individuals with co-existing type 2 diabetes or more complex metabolic disease;
- as part of structured, algorithm-led obesity care, rather than as a stand-alone intervention.
Particular relevance for people living with diabetes
Another recurring theme was the close relationship between amylin biology and glucose regulation. In clinical discussions, this raised the possibility that amylin-based therapies may be particularly relevant for people living with obesity and type 2 diabetes, where both weight and glycaemic control are priorities—always subject to individual assessment, licensing and guideline updates.
While long-term outcomes continue to be studied, the tone throughout ECO was one of cautious optimism: enthusiasm balanced with a clear need for real-world data and structured implementation.
The bigger picture: obesity, inflammation and cancer risk
Beyond metabolic disease, obesity was repeatedly linked to systemic inflammation and hormonal dysregulation—mechanisms increasingly associated with the development of certain cancers.
This reinforces an important message for patients and clinicians alike: treating obesity effectively may reduce the burden of multiple downstream diseases, even when weight loss itself is not the only objective.
“How will clinicians decide who gets which medication?”
One of the most practical questions raised during the amylin symposium was how clinicians will decide which patients should receive which medications as options expand.
The response was clear: this future is structured, not experimental. Medication choice is already guided by the European Association for the Study of Obesity (EASO) treatment algorithm, which considers complications, metabolic health and treatment goals beyond weight alone.
The EASO framework distinguishes between weight-focused care and complications-driven care, aiming to integrate newer therapies safely rather than adopting them in isolation. For readers who want the source material, EASO publishes its pharmacological treatment framework here: EASO pharmacological treatment framework.
What that can mean in practice (simplified)
- Clinicians look at heart and blood-vessel risk, kidney health and other complications—not only BMI.
- Blood sugar patterns and diabetes status influence whether intensifying or combining pathways could be appropriate.
- Your personal goals (mobility, sleep apnoea, glycaemic targets, joint symptoms) help set priorities alongside weight change.
- Decisions are revisited over time: obesity care is increasingly longitudinal, like hypertension or type 2 diabetes follow-up.
Obesity care is beginning to resemble hypertension and diabetes care
An important insight from ECO was the growing parallel between obesity and other chronic conditions such as hypertension and diabetes. In those conditions, combination and sequential therapies are routine, reflecting the fact that multiple biological pathways contribute to disease. Obesity care appears to be following the same trajectory.
Combination therapies—including those leveraging both amylin and GLP-1 biology—were discussed as a natural evolution rather than a radical shift, particularly for patients who plateau on single-pathway treatments.
What this means for patients starting their journey now
For patients considering weight-loss treatment today, discussions about future therapies may feel distant. However, one of the most reassuring messages from ECO was that starting treatment now does not close doors—it often opens them.
Patients with higher BMI ranges who begin evidence-based treatment today may achieve meaningful weight loss and improvement in health risks, while remaining well positioned to benefit from additional options in the future should progress plateau.
This aligns with the EASO emphasis on reviewing and adapting treatment over time, rather than viewing obesity care as a single intervention.
Looking ahead
Professor Donna Ryan’s “Looking ahead” session captured the overall tone of ECO 2026: forward-looking, but grounded. Amylin-based therapies were presented not as quick fixes, but as part of a more mature phase of obesity medicine—one that prioritises long-term health, structured decision-making and biological understanding.
While newer combinations attract attention, licensed GLP-1-based treatments remain the backbone of care today for many eligible adults in the UK. Our clinical team can help you understand whether a prescription weight-management pathway is suitable and how it fits your history and goals.
View our current weight loss treatments Check your eligibility
Emerging therapies (summary)
Congress presentations may differ from final peer-reviewed publications and regulatory labels. If you are currently using a licensed medicine such as Wegovy® or Mounjaro™, continue to follow your prescriber’s instructions unless they advise a change.
Disclaimer
This article is for general information only and does not replace personalised medical advice. It reflects themes discussed at ECO / EASO 2026 and related literature, not PrivateDoc prescribing policy. Always speak to a qualified clinician before starting or changing treatment.
